anti igm (Valiant)

Valiant is a verified supplier

Valiant manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Valiant anti igm
BH3 profiling demonstrates that primary CLL cells stimulated in vitro with <t>anti-IgM</t> or CXCL12 are less primed to undergo apoptosis and that priming can be restored with <t>CAL-101.</t> (A-B) PB-derived CLL cells from 4 individual patients were stimulated with

BH3 profiling demonstrates that primary CLL cells stimulated in vitro with <t>anti-IgM</t> or CXCL12 are less primed to undergo apoptosis and that priming can be restored with <t>CAL-101.</t> (A-B) PB-derived CLL cells from 4 individual patients were stimulated with

Anti Igm, supplied by Valiant, used in various techniques. Bioz Stars score: 88/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti igm/product/Valiant
Average 88 stars, based on 10 article reviews
Price from $9.99 to $1999.99

anti igm - by Bioz Stars, 2022-12

88/100 stars

Images

1) Product Images from "Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia"

Article Title: Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

Journal: Blood

doi: 10.1182/blood-2012-02-414060

BH3 profiling demonstrates that primary CLL cells stimulated in vitro with anti-IgM or CXCL12 are less primed to undergo apoptosis and that priming can be restored with CAL-101. (A-B) PB-derived CLL cells from 4 individual patients were stimulated with

Figure Legend Snippet: BH3 profiling demonstrates that primary CLL cells stimulated in vitro with anti-IgM or CXCL12 are less primed to undergo apoptosis and that priming can be restored with CAL-101. (A-B) PB-derived CLL cells from 4 individual patients were stimulated with

Techniques Used: In Vitro, Derivative Assay

2) Product Images from "The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo"

Article Title: The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

Journal: Blood

doi: 10.1182/blood-2011-10-386417

Abrogation of signaling downstream of the BCRs and of CXCR4 and CXCR5 receptors. Displayed are immunoblots from CLL cells from 1 representative patient of 9 patients, that were either unstimulated or stimulated for 10 minutes with anti-IgM (αIgM,

Figure Legend Snippet: Abrogation of signaling downstream of the BCRs and of CXCR4 and CXCR5 receptors. Displayed are immunoblots from CLL cells from 1 representative patient of 9 patients, that were either unstimulated or stimulated for 10 minutes with anti-IgM (αIgM,

Techniques Used: Western Blot

PCI-32765 inhibits anti-IgM and NLC-mediated prosurvival signals in CLL cells. (A) Contour plots of a representative CLL sample, depicting CLL cell viabilities after 24, 48, and 72 hours of incubation with anti-IgM in the presence or absence of PCI-32765,

Figure Legend Snippet: PCI-32765 inhibits anti-IgM and NLC-mediated prosurvival signals in CLL cells. (A) Contour plots of a representative CLL sample, depicting CLL cell viabilities after 24, 48, and 72 hours of incubation with anti-IgM in the presence or absence of PCI-32765,

Techniques Used: Incubation

3) Product Images from "The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia"

Article Title: The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

Journal: Blood

doi: 10.1182/blood-2011-05-352492

CAL-101 inhibits signaling downstream of the BCR, CXCR4 and CXCR5. In vivo, CAL-101 reduces plasma chemokine levels, impairs AKT activation, and induces lymphocytosis in CLL patients. (A) CLL cells were activated with anti-IgM, or CXCL12, or CXCL13 in

Figure Legend Snippet: CAL-101 inhibits signaling downstream of the BCR, CXCR4 and CXCR5. In vivo, CAL-101 reduces plasma chemokine levels, impairs AKT activation, and induces lymphocytosis in CLL patients. (A) CLL cells were activated with anti-IgM, or CXCL12, or CXCL13 in

Techniques Used: In Vivo, Activation Assay

Specific PI3Kδ inhibition with CAL-101 induces CLL apoptosis and abrogates BCR-derived survival signals. (A) CLL cells were incubated in medium alone (control), medium containing 10 μg/mL of anti-IgM mAbs, or medium with anti-IgM mAbs

Figure Legend Snippet: Specific PI3Kδ inhibition with CAL-101 induces CLL apoptosis and abrogates BCR-derived survival signals. (A) CLL cells were incubated in medium alone (control), medium containing 10 μg/mL of anti-IgM mAbs, or medium with anti-IgM mAbs

Techniques Used: Inhibition, Derivative Assay, Incubation

anti igm (Valiant)

Structured Review

Images

1) Product Images from "Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia"

2) Product Images from "The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo"

3) Product Images from "The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia"

Similar Products

Image Search Results